Sunovion
Also known as: Elevation Pharmaceuticals, Inc.(now known as Sunovion Respiratory Development Inc.) | Elevation Pharmaceuticals, Inc., (now known as Sunovion Respriatory Developement Inc.) | Sepracor | Sepracor Incorporated, 84 Waterford Drive, Marlborough, MA 01752 | Sunovioin | Sunovion | SUNOVION | Sunovion Pharamceuticals Inc. | Sunovion Pharmacetuicals Inc. | Sunovion Pharmaceuticals | Sunovion Pharmaceuticals In. | SUNOVION PHARMS INC | SUNOVION RESP | Sunovion Respiratory Development | Sunovion Respiratory Development Inc. | Sunovion Respiratory Director
Highest phase reached
Phase 4
First clinical trial
Nov 1, 2000First marketed drug
Mar 25, 1999First NDA
Mar 25, 1999Last known activity
Nov 24, 2022
Timeline
1980s
- Jul 1, 1984
Sunovion— Founded
2000s
- Dec 1, 2009
Sumitomo Dainippon— Acquired By
2010s
- Jul 1, 2011
indacaterol— NDA Secondary Org
- Aug 30, 2012
Elevation Pharmaceuticals, Inc.— Acquired
- Nov 8, 2013
eslicarbazepine acetate— NDA Organization
- Aug 31, 2016
Cynapsus Therapeutics Inc.— Acquired
2020s
- May 21, 2020
apomorphine— Marketing Organization
Drugs by trial phase (47 distinct, 192 trials)
Phase 4 (15 own, 1 via acquisition)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (5 own, 3 via acquisition)
Phase 1 (9 own, 1 via acquisition)
Indications
Approved for
Studied for
- Acute Coronary Syndrome
- Alzheimer Disease
- Anxiety Disorders
- Apnea
- Arthritis
- Arthritis, Rheumatoid
- Asthma
- Asthma, Exercise-Induced
- Attention Deficit Disorder with Hyperactivity
- Autistic Disorder
- Back Pain
- Binge-Eating Disorder
- Bipolar Disorder
- Bronchial Hyperreactivity
- Bronchial Spasm
- Bronchitis
- Bronchitis, Chronic
- Bulimia
- Cerebral Infarction
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Emphysema
- Epilepsies, Partial
- Epilepsy
- Feeding and Eating Disorders
- Fibromyalgia
- Hyperkinesis
- Inflammation
- Ischemia
- Low Back Pain
- Lung Diseases
- Lung Diseases, Obstructive
- Major Depressive Disorder
- Mental Disorders
- Migraine Disorders
- Myofascial Pain Syndromes
- Neoplasms
- Parasomnias
- Parkinson Disease
- Psychotic Disorders
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Respiratory Aspiration
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal
- Schizophrenia
- Seizures
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Sleep Initiation and Maintenance Disorders
- Sleep Wake Disorders
- Status Asthmaticus
- Stroke
- Syndrome
- Tobacco Use Disorder
- Urinary Bladder, Overactive
Marketed drugs (9)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT05628103Study chairPhase 3Nov 24, 2022
- NCT05628103Lead sponsorPhase 3Nov 24, 2022
- NCT05542264Lead sponsorPhase 1Nov 15, 2022
- NCT05542264Study chairPhase 1Nov 15, 2022
- NCT05463770Lead sponsorPhase 1Aug 30, 2022
- NCT05463770Study directorPhase 1Aug 30, 2022
- NCT05402111Study directorPhase 1Jun 13, 2022
- NCT05402111Lead sponsorPhase 1Jun 13, 2022
- NCT05227209Study chairPhase 3Mar 17, 2022
- NCT05227209Lead sponsorPhase 3Mar 17, 2022
- NCT04865835Study chairPhase 1May 12, 2021
- NCT04865835Lead sponsorPhase 1May 12, 2021
- NCT04383691CollaboratorPhase 3Jun 30, 2020
- NCT04369391Lead sponsorPhase 1May 15, 2020
- NCT04369391Study chairPhase 1May 15, 2020
Details
- Founded
- Marlborough, MA, US Jul 1, 1984
- First NDA
- Mar 25, 1999
- Last known activity
- Nov 24, 2022
Notes
Acquired by Dainipppon Sumitomo 3 Sept 2009 Previously known as Sepracor